ClinicalTrials.gg
TerminatedNCT01277289CrodexUpdated Jun 3, 2024Results posted

Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease

A Phase 3 interventional study of Dexamethasone in Crohn's Disease, sponsored by Quince Therapeutics S.p.A.. Terminated at 8 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-06-03.

Sponsored by Quince Therapeutics S.p.A. · Phase 3, Interventional, and Treatment

Why this study was terminated
due to the difficulty to enroll suitable patients

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Jun 2009, registered Jan 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 205 studies in Crohn Disease with a site in Italy — 54 open to participants now, 78 under way, 29 of them phase 3. Crohn Disease · Italy.

Enrollment
127th of 163
51 · median 187
Started
2009
the only one that year
Phase 3
78 of 205
18 open now
Registered
19th of 205
by date

Among the 205 studies in Crohn Disease with a site in Italy, this one is the 127th largest by enrollment of the 163 interventional ones that give a count, is the only one that started in 2009, is one of 78 in phase 3, and was the 19th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

54 of the 205 studies in Crohn Disease with a site in Italy are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Crohn Disease with a site in Italy, or all of them as a file.
02

Study summary

Primary objective:

Assessment of the efficacy of EryDex vs PLACEBO in maintaining patients with steroid-dependent Crohn's disease in clinical remission throughout 12 months without oral steroids.

Secondary objectives:

  1. safety of EryDex
  2. emergence of new adverse effects from steroids or disappearance of those possibly pre-existing in the various subgroups of patients;
  3. duration of the period of remission;
  4. evaluation of the hypophysis-adrenal function;
  5. study of plasma concentrations of dexamethasone;
  6. effect of therapy on the metabolism of calcium and on indexes of inflammation;
  7. assessing the quality of life;
  8. rate of surgical resection
  9. evaluation of the indirect costs of care.
Read the detailed description

This was a multicenter, randomized, double-blind, PLACEBO-controlled, parallel-group study comparing EryDex versus PLACEBO. Patients with steroid-dependent Crohn's disease were enrolled and randomized to undergo 12 infusions of intraerythrocyte dexamethasone (EryDex), or PLACEBO. A balanced (1:1) randomization between the two treatment groups (EryDex / PLACEBO) was employed.

At the time of randomization, study patients were stratified at each study site according to their previous therapy with AZT/6MP/MTX (never treated with AZT/6MP/MTX or intolerant/resistant to the therapy with AZT/6MP/MTX). The treatment was planned to be performed with 12 monthly infusions of EryDex or PLACEBO.

Patients were followed-up after completion of the treatment for 6 months in patients regularly completing the study and 3 months in patients discontinuing from the study prematurely. The evaluation of the primary and secondary objectives was to be done at the 12th month of study (one month after the last study drug infusion), or upon relapse.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • dexamethasone
  • ery-dex
  • Chron's disease
  • CD
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects;
  2. Age > 18 years;
  3. Patients with -dependent Crohn's disease, documented in the medical history, having suffered from at least one episode of relapse (CDAI > 150) in the last 12 months. Patients should have been in clinical remission (CDAI \< 150) for at least four weeks, on stable therapy with at least 10 mg of methylprednisolone (or equivalent), or been on steroidal tapering after a recent relapse. Patients with intolerance or resistance to AZT/6-MP/MTX were eligible;
  4. Patients willing and able to give written .

Exclusion criteria

Exclusion Criteria:

  1. Patients with Crohn's disease with intestinal sub-occlusion, or suspect of abdominal abscess, or with active perianal disease, or with clinically active disease at randomization (CDAI ≥150);
  2. Patients already on therapy with agents (AZT, 6-MP, MTX) for less than 4 months;
  3. Patients having received therapy with infliximab (or other anti-TNF) in the previous 3 months;
  4. treatments in the previous 3 months prior to randomization;
  5. Pregnant women, or women who were not using valid birth-control measures, except those in surgical menopause; breast feeding;
  6. Non collaborating subjects or those unable to be compliant with the treatment and the study schedules;
  7. Severe concomitant diseases such as :

    1. patients with inadequate "bone marrow reserve": WBC \< 3000 /mm3; PLTs \< 75000 /mm3; \< 8 g/dl
    2. liver disease with total ≥ 3 times the (ULN), (GOT) ≥ 3x ULN, alkaline phosphatase ≥ 3x ULN
    3. renal disease with serum creatinine ≥ 3 mg/dl
    4. serious cardiac, allergic, lung, neurological diseases, neoplastic or pre-neoplastic disease
    5. diseases (other than Crohn's) requiring chronic treatment;
  8. Elective surgery already scheduled at the start of the study (NB: patients having undergone previous surgery for Crohn's disease could be enrolled, if the patient had fully recovered and had been in remission for at least 4 weeks);
  9. Chronic use of alcohol; drug addiction;
  10. Subjects with to the use of steroids (i.e. systemic fungal infections);
  11. Evidence of clostridium difficilis in the stools.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Ery-dex

    Ery-dex (dexamethasone sodium phosphate)is administered as intra-erythrocyte drug at monthly interval

    Drug: Dexamethasone

  • Placebo comparator
    Placebo

    placebo comparator (sodium chloride instead of dexamethasone sodium phosphate) is administered in infusion at monthly interval.

    Drug: Dexamethasone

Interventions

  • 500 mg/20 ml encapsulated in erythrocytes, every month for 12 months

    Also known as: Ery-dex

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Maintaining Steroids-free Clinical Remission (CDAI<150) Without Surgery for 12 Months

    Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) \< 150. A therapy failure was considered to have occurred in patients with a CDAI score over 150 for \> 2 weeks and/or the need for systemic steroids (with / without surgery). Hence, the higher the index, the worse the outcome.

    Time frame: after 12 months

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    This evaluation of safety was made by the comparison of treatment emergent adverse events (TEAE). Treatment emergent adverse events (TEAE) are undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment.

    Time frame: after 12 months

  2. Percentage of Patients Interrupting the Study Because of Adverse Events

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: after 12 months

  3. Duration of the Period of Steroid-free Clinical Remission

    The mean time between the end of the steroid therapy and a confirmed relapse of the disease.

    Time frame: From end of the steroid therapy to relapse, up to 545 days

  4. Dosing of Serum Cortisol

    Levels of serum cortisol were measured at baseline and following Adrenocorticotropic Hormone (ACTH) trigger.

    Time frame: At Baseline and at the end of the study (18 months)

07

Results

Posted Jun 3, 2024

Participant flow

There were 63 patients enrolled into the screening phase at 10 sites; of these, 51 patients (representing the Safety population) were randomized at 9 sites.

Participant flow — Overall Study
MilestoneEry-dexPlacebo
Started2823
Completed52
Not completed2321
Withdrew: Fragile vein10
Withdrew: Physician decision10
Withdrew: Therapy failure and/or crohn's surgery1316
Withdrew: Protocol violation11
Withdrew: Adverse event21
Withdrew: Consent withdrawn11
Withdrew: Premature closure of the study42

Outcome measures

PrimaryPercentage of Patients Maintaining Steroids-free Clinical Remission (CDAI<150) Without Surgery for 12 Months

Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) \< 150. A therapy failure was considered to have occurred in patients with a CDAI score over 150 for \> 2 weeks and/or the need for systemic steroids (with / without surgery). Hence, the higher the index, the worse the outcome.

Time frame:
after 12 months
Reported as:
Count of participants · Participants
Percentage of Patients Maintaining Steroids-free Clinical Remission (CDAI<150) Without Surgery for 12 Months
ParticipantsEry-dexPlacebo
Percentage of Patients Maintaining Steroids-free Clinical Remission (CDAI<150) Without Surgery for 12 Months52
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

This evaluation of safety was made by the comparison of treatment emergent adverse events (TEAE). Treatment emergent adverse events (TEAE) are undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment.

Time frame:
after 12 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsEry-dexPlacebo
Number of Participants With Treatment Emergent Adverse Events (TEAEs)136
SecondaryPercentage of Patients Interrupting the Study Because of Adverse Events

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Time frame:
after 12 months
Reported as:
Count of participants · Participants
Percentage of Patients Interrupting the Study Because of Adverse Events
ParticipantsEry-dexPlacebo
Percentage of Patients Interrupting the Study Because of Adverse Events21
SecondaryDuration of the Period of Steroid-free Clinical Remission

The mean time between the end of the steroid therapy and a confirmed relapse of the disease.

Time frame:
From end of the steroid therapy to relapse, up to 545 days
Reported as:
Mean · Days
Duration of the Period of Steroid-free Clinical Remission
DaysEry-dexPlacebo
Duration of the Period of Steroid-free Clinical Remission55.3 ± 73.284.9 ± 72.9
SecondaryDosing of Serum Cortisol

Levels of serum cortisol were measured at baseline and following Adrenocorticotropic Hormone (ACTH) trigger.

Time frame:
At Baseline and at the end of the study (18 months)
Reported as:
Mean · μg/dl
Dosing of Serum Cortisol
μg/dlEry-dexPlacebo
At Baseline - before ACTH6.8 ± 4.67.1 ± 6.2
At the end of the study - before ACTH11.3 ± 8.66.4 ± 5.4
At baseline - after ACTH10.3 ± 7.611.0 ± 6.5
At the end of the study - after ACTH18.4 ± 4.712.7 ± 7.6

Adverse events

Collected over Adverse events were collected from Visit 1 ( Day 15) up to Visit 15 (Day 600). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ery-dex0/28 (0%)6/28 (21.4%)19/28 (67.9%)
Placebo1/23 (4.3%)4/23 (17.4%)16/23 (69.6%)
Most frequent serious events
Most frequent serious events
EventEry-dexPlacebo
SubileusGastrointestinal disorders1/283/23
Crohn's diseaseGastrointestinal disorders2/280/23
Staphylococcal infectionInfections and infestations0/281/23
Gastrointestinal haemorrhageGastrointestinal disorders1/280/23
Intestinal obstructionGastrointestinal disorders1/280/23
Spinal fractureInjury, poisoning and procedural complications1/280/23
Most frequent other events
Showing 10 of 59
Most frequent other events
EventEry-dexPlacebo
AstheniaGeneral disorders3/284/23
CushingoidEndocrine disorders4/280/23
SubileusGastrointestinal disorders2/283/23
HeadacheNervous system disorders0/283/23
InfluenzaRespiratory, thoracic and mediastinal disorders3/283/23
NauseaGastrointestinal disorders3/282/23
IrritabilityGeneral disorders3/282/23
InsomniaPsychiatric disorders3/282/23
Iron deficiency anaemiaBlood and lymphatic system disorders0/282/23
VomitingGastrointestinal disorders1/282/23

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ery-dexPlaceboTotal
<=18 years000
Between 18 and 65 years242044
>=65 years437
Age, Continuous
Age, Continuous(years)Ery-dexPlaceboTotal
Mean47.3 ± 14.943.4 ± 12.545.5 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)Ery-dexPlaceboTotal
Female20727
Male81624
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ery-dexPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White282351
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Ery-dexPlaceboTotal
Romania101
Italy272249
Spain011
08

Study locations

8 sites
  • Policlinico Sant'Orsola
    Bologna, 40138, Italy
  • Ospedale Careggi
    Firenze, 50100, Italy
  • Ospedale Cervello
    Palermo, 90100, Italy
  • Complesso Integrato Columbus
    Rome, 00100, Italy
  • Ospedale San Camillo
    Rome, 00152, Italy
  • A.O. San Donato
    San Donato Milanese, 20097, Italy
  • Spitalul Clinic Judetean De Urgenta
    Cluj-Napoca, 400006, Romania
  • Clinic CIBER EHD
    Barcelona, 08036, Spain
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2009 to primary completion in Dec 2011, 30 months.

Results were first posted in Jun 2024, 12 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2011
First posted
Jan 14, 2011
StartActual
Jun 3, 2009
Primary completionActual
Dec 30, 2011
CompletionActual
Jun 2012
Results first posted
Jun 3, 2024
Last update
Jun 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01277289
Lead sponsor
Quince Therapeutics S.p.A.
Responsible party
Sponsor
First posted
Jan 14, 2011
Start date
Jun 3, 2009
Primary completion
Dec 30, 2011
Completion
Jun 2012
Results posted
Jun 3, 2024
Last update
Jun 3, 2024

Study contacts

Angelo Andriulli, MD
principal investigator · Unafilliated

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion